drugset / Trial / NCT02529241
An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To investigate pharmacokinetics, safety and tolerability of LCB01-0371, LCB01-0371-B after a single oral dose in healthy male subjects. To investigate safety, tolerability of LCB01-0371 after a single oral dose in healthy male subjects.
Timeline
- Start
- 2015-07
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Delpazolid | Small molecule | 400 mg | Oral |
| Subject | Delpazolid | Small molecule | 800 mg | Oral |
| Subject | Delpazolid | Small molecule | 1200 mg | Oral |
Indications
No indication recorded.